Eli Lilly’s Zepbound takes on Novo Nordisk’s Wegovy in obesity drug showdown
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo Nordisk’s Wegovy (semaglutide) in a recent clinical trial. …